Compliance has been repeatedly demonstrated to inversely correlate with the presence of psychiatric disorders in IBD cohorts [66,67]; the co-occurrence of anxiety and mood disorders significantly increased the risk of discontinuation in the first year following anti-TNF initiation (hazard ratio, 1.50; 95% CI, 1.15–1.94) and the overall risk of discontinuation of anti-TNF therapy (adjusted hazard ratio, 1.28; 95%, CI, 1.03–1.59) [67]. This evidence concerns the gene TNF and mood disorder.